BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142-1149. [PMID: 20389296 DOI: 10.1038/ajg.2010.158] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015;13:1118-24.e3. [PMID: 25562796 DOI: 10.1016/j.cgh.2014.12.026] [Cited by in Crossref: 102] [Cited by in F6Publishing: 88] [Article Influence: 14.6] [Reference Citation Analysis]
2 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
3 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
4 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
5 Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015; Jul 15. [Epub ahead of print]. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Chapman TP, Gomes CF, Louis E, Colombel J, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020;5:63-79. [DOI: 10.1016/s2468-1253(19)30186-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
7 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
8 Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 106] [Article Influence: 11.6] [Reference Citation Analysis]
9 Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, Phelip JM, Peyrin-biroulet L, Colombel JF, Del Tedesco E, Paul S, Flourie B. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther 2017;46:142-9. [DOI: 10.1111/apt.14106] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
10 Hashash JG, Regueiro MD. The great debate: stopping immunomodulators and biologics in Crohn’s disease patients in remission. Expert Rev Gastroenterol Hepatol. 2013;7:501-503. [PMID: 23984997 DOI: 10.1586/17474124.2013.814933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 González-Lama Y, Gisbert JP. Monitoring thiopurine metabolites in inflammatory bowel disease. Frontline Gastroenterol 2016;7:301-7. [PMID: 28839871 DOI: 10.1136/flgastro-2015-100681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
12 Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55. [PMID: 24393836 DOI: 10.1038/nrgastro.2013.253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 13.5] [Reference Citation Analysis]
13 Kim YS. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]. Korean J Gastroenterol 2018;71:74-80. [PMID: 29471604 DOI: 10.4166/kjg.2018.71.2.74] [Reference Citation Analysis]
14 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
15 Qualia CM, Bousvaros A. Advances in Pediatric IBD. Curr Pediatr Rep 2013;1:206-13. [DOI: 10.1007/s40124-013-0020-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Sparrow MP, Melmed GY, Devlin S, Kozuch P, Raffals L, Loftus Jr EV, Rubin DT, Spiegel B, Baidoo L, Bressler B, Cheifetz A, Irving P, Jones J, Kaplan GG, Velayos F, Siegel CA. De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel. GastroHep 2019;1:108-17. [DOI: 10.1002/ygh2.337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Einarson TR, Bereza BG, Ying Lee X, Lelli F. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 2017;33:1433-49. [DOI: 10.1080/03007995.2017.1335001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Chaparro M. Novedades sobre los tratamientos para la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2013;36:21-9. [DOI: 10.1016/s0210-5705(13)70050-5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
20 Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826. e2. [PMID: 21530748 DOI: 10.1053/j.gastro.2010.11.058] [Cited by in Crossref: 268] [Cited by in F6Publishing: 238] [Article Influence: 24.4] [Reference Citation Analysis]
21 Filippi J, Laharie D, Michiels C, Flamand M, Bouguen G, Nancey S, Presles E, Paul S, Schneider S, Hébuterne X. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience. J Crohns Colitis. 2015;9:252-258. [PMID: 25588386 DOI: 10.1093/ecco-jcc/jjv001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
22 Ungar B, Ben-shatach Z, Ben-haim G, Yavzori M, Picard O, Fudim E, Kopylov U, Veyrard P, Del Tedesco É, Paul S, Eliakim R, Ben-horin S, Roblin X. Infliximab therapy intensification upon loss of response: Is there an optimal trough level? Digestive and Liver Disease 2019;51:1106-11. [DOI: 10.1016/j.dld.2019.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 2012;28:341-8. [PMID: 22573191 DOI: 10.1097/MOG.0b013e328354567f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
24 Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis 2017;11:263-73. [PMID: 27797918 DOI: 10.1093/ecco-jcc/jjw188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
25 Zhang T, Wang Z, Fan R, Zhang M, Lin Y, Hong L, Zhou X, Hu S, Cheng M, Zhong J. The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China. Biomed Res Int 2016;2016:8648307. [PMID: 27896276 DOI: 10.1155/2016/8648307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338-353. [PMID: 24957164 DOI: 10.1111/apt.12838] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
27 Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174-179. [PMID: 21674731 DOI: 10.1002/ibd.21792] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
28 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 17.8] [Reference Citation Analysis]
29 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
30 Hirten RP, Lakatos PL, Halfvarson J, Colombel JF. A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2020;18:1336-45. [PMID: 31887444 DOI: 10.1016/j.cgh.2019.12.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Ben-horin S, Mao R, Qiu Y, Chen M. Discontinuation of Biological Treatments in Inflammatory Bowel Disease: A Concise Pragmatic Review. Journal of Clinical Gastroenterology 2018;52:6-12. [DOI: 10.1097/mcg.0000000000000938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
33 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
34 Frias Gomes C, Colombel JF, Torres J. De-escalation of Therapy in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20:35. [PMID: 29961926 DOI: 10.1007/s11894-018-0643-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
35 Sharifi A, Hosseinzadeh-Attar MJ, Vahedi H, Nedjat S. A randomized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patients. Saudi J Gastroenterol. 2016;22:316-323. [PMID: 27488327 DOI: 10.4103/1319-3767.187606] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
36 Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther. 2011;34:1-10. [PMID: 21539588 DOI: 10.1111/j.1365-2036.2011.04679.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 8.0] [Reference Citation Analysis]
37 Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 [PMID: 33244205 DOI: 10.3748/wjg.v26.i41.6455] [Reference Citation Analysis]
38 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
39 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
40 Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, Ashworth L, Hauenstein S, Heiner L, Chuang E, Singh S, Bousvaros A. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis 2015;21:307-14. [PMID: 25569737 DOI: 10.1097/MIB.0000000000000284] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
41 Fischer M, Campbell SC, Calley CSJ, Helper DJ, Chiorean MV, Fadda HM. Risk Factors for Rescue Therapy in Crohn’s Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up. Dig Dis Sci 2017;62:3131-7. [DOI: 10.1007/s10620-017-4771-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
42 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
43 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
44 Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 2015;27:804-12. [PMID: 25933126 DOI: 10.1097/MEG.0000000000000378] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
45 Ong DE, Kamm MA, Hartono JL, Lust M. Addition of thiopurines can recapture response in patients with Crohn’s disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013;28:1595-1599. [PMID: 23662928 DOI: 10.1111/jgh.12263] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
46 Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794. [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055] [Cited by in Crossref: 1157] [Cited by in F6Publishing: 1053] [Article Influence: 105.2] [Reference Citation Analysis]
47 Louis E. Immunosuppressant combined with infliximab in Crohn's Disease: for 6 months, for 2 years, or forever? Inflamm Bowel Dis. 2011;17:858-859. [PMID: 20593432 DOI: 10.1002/ibd.21407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology. 2015;149:1716-1730. [PMID: 26381892 DOI: 10.1053/j.gastro.2015.08.055] [Cited by in Crossref: 119] [Cited by in F6Publishing: 109] [Article Influence: 17.0] [Reference Citation Analysis]
49 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
50 Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A, Camila-Dias C, Macedo G. High C-reactive protein in Crohn’s disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8:129-136. [PMID: 23932786 DOI: 10.1016/j.crohns.2013.07.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
51 Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:1100-1110. [PMID: 21971373 DOI: 10.1097/MEG.0b013e32834b9544] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
52 Lambrescak E, Vaysse T, Allez M, Ungar B, Gleizes A, Hacein-Bey S, Chowers Y, Roblin X, Kopylov U, Rachas A, Carbonnel F. Duration of combination therapy and risk of treatment failure in patients with inflammatory bowel disease. Clin Res Hepatol Gastroenterol 2021;45:101503. [PMID: 32893176 DOI: 10.1016/j.clinre.2020.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11331-11342 [PMID: 26525434 DOI: 10.3748/wjg.v21.i40.11331] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342-1348.e1. [PMID: 24407106 DOI: 10.1016/j.cgh.2013.12.030] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
55 Ampuero J, Rojas-Feria M, Castro-Fernández M, Millán-Lorenzo M, Guerrero-Jiménez P, Romero-Gómez M. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's Disease in clinical practice. J Gastroenterol Hepatol. 2015;Epub ahead of print. [PMID: 26173493 DOI: 10.1111/jgh.13039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
56 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 470] [Article Influence: 72.5] [Reference Citation Analysis]
57 Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. Dig Liver Dis 2014;46:1066-71. [PMID: 25169961 DOI: 10.1016/j.dld.2014.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 2020;14:351-60. [DOI: 10.1093/ecco-jcc/jjz152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
59 Corte C, Saxena P, Tattersall S, Selinger C, Leong RW. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:1141-9. [PMID: 22188169 DOI: 10.1111/j.1440-1746.2011.07056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
60 Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277-1290. [PMID: 27329436 DOI: 10.1080/14712598.2016.1203897] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
61 Giri S, Ingawale S, Angadi S. Immunomodulator Withdrawal From Anti-TNF Therapy Needs a Careful Patient Selection. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00136-7. [PMID: 35151860 DOI: 10.1016/j.cgh.2022.02.012] [Reference Citation Analysis]
62 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
63 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]